Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
May 12, 2022 16:05 ET
|
Viridian Therapeutics, Inc
-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022...
Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
May 03, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved...